Publications that Will Change the Way You Inject and Consent
Recent studies on the risks of vascular occlusions and the safety of cannulas versus needles have impacted the way Dr. Robyn Siperstein educates and consents her patients. Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Siperstein, a dermatologist in Boca Raton and Boynton Beach, Fla. Hear why Dr. Siperstein says a paper by Dr. Murad …
Recent studies on the risks of vascular occlusions and the safety of cannulas versus needles have impacted the way Dr. Robyn Siperstein educates and consents her patients. Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Siperstein, a dermatologist in Boca Raton and Boynton Beach, Fla. Hear why Dr. Siperstein says a paper by Dr. Murad … Continue reading "Publications that Will Change the Way You Inject and Consent"
Alopecia areata (AA) is a common autoimmune disorder. Although its pathogenesis is not fully understood, AA involves CD8 T cell-mediated destruction of the hair follicle. Several treatment options exist; however, there is minimal evidence in the pediatric population. Currently, there are no curative treatments for AA. The literature suggests that Janus kinase (JAK) inhibitors may be an effective t … 
In this June edition of the Journal of Drugs in Dermatology (JDD), we're excited to showcase a selection of groundbreaking research and expert insights that delve into the latest advancements and treatments in dermatology. From innovative acne scar therapies to in-depth analyses of topical acne treatments, this month's featured articles provide a comprehensive overview of current dermatological … 
Skin boosters are a new category of injectables approved by the FDA. These products are low concentration hyaluronic acid gels that improve skin quality, including smoothness, luminosity and hydration. Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Terrence Keaney, associate clinical professor of dermatology at GW School of Medicine & … 
Cemiplimab is a monoclonal antibody therapy that has emerged as a promising treatment option for certain types of advanced skin cancer. Specifically designed to target the programmed cell death protein 1 (PD-1) pathway, cemiplimab works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby unleashing the body's immune system to recognize and attack cancer cells. We con …